Cart
Your cart is empty
Find
Small-molecule NNMT inhibitor
A methylquinolinium small molecule that inhibits nicotinamide N-methyltransferase (NNMT). Supplied as a lyophilized powder for research purposes only.
Launch Sale · Ends Nov 6
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
Not a peptide — a methylquinolinium small molecule. 5-Amino-1MQ blocks nicotinamide N-methyltransferase (NNMT), the enzyme that consumes methyl groups and nicotinamide to make 1-methylnicotinamide. Shut that reaction down and the cell stops bleeding methyl donors into a metabolic dead end.
The research interest follows directly from the chemistry: inhibit NNMT and labs ask what happens to the NAD+ salvage pool and to SAM-dependent methylation downstream. That is the question most of the published work is built around.
The compound is studied mostly as a probe of NNMT itself: how potently it occupies the enzyme, and what that occupancy does to the NAD+ salvage pool, SAM-dependent methylation, and adipocyte metabolism. Mitochondrial and cardiac NAD+ work has been added more recently.
As an NNMT inhibitor, 5-Amino-1MQ is used in work that treats the methylation–NAD+ junction as a metabolic lever. Cell and tissue models examine what happens when the enzyme is taken out of the loop — chiefly the effect on the NAD+ salvage pathway and on adipocyte energy handling.
The structure–activity paper from Neelakantan and colleagues anchors the chemistry; later studies extend it into NAD+ homeostasis and mitochondrial readouts, building the case for NNMT as a tractable metabolic target.
Interest in the molecule starts with the enzyme. Once NNMT was tied to obesity-related metabolic dysfunction, the field went looking for cell-permeable inhibitors, and methylquinolinium scaffolds — 5-Amino-1MQ among them — came out of that medicinal-chemistry effort.
Work since has used it largely as a tool compound: a clean way to ask what a cell does when NNMT activity drops.
In vitro and animal studies
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and in doing so consumes both the methyl donor SAM and the NAD+ precursor pool. NNMT is highly expressed in adipose tissue, and its expression rises in obesity — the observation that made inhibition an attractive target.
The foundational work is cell and rodent based. In cultured adipocytes, NNMT knockdown and pharmacological inhibition were reported to increase cellular NAD+ and SAM, raise sirtuin activity, and increase energy expenditure at the cell level. In diet-induced obese mice, 5-Amino-1MQ administration was reported to reduce fat mass and body weight without a corresponding reduction in food intake — a mechanistically important detail, since it distinguishes the effect from appetite suppression.
A separate strand examines skeletal muscle, where NNMT inhibition has been studied in the context of muscle stem cell function and age-related decline. The compound is a small molecule rather than a peptide, so it is orally available in the animal work, and it is one of the few items in this catalogue where that is straightforwardly true.
Two features of the compound's chemistry shape how its literature should be read. It is a quaternary ammonium quinolinium — permanently charged at physiological pH — which affects membrane permeability and tissue distribution in ways that differ substantially from the neutral small molecules it is often grouped with. And it functions as a substrate-competitive inhibitor, a methyl-accepting analogue that occupies the NNMT active site, so its effect depends on the local concentration of the natural substrate rather than acting as a simple on-off switch. Published inhibitory potency figures should be read against that competition rather than as absolute values.
A further complication is that NNMT expression varies enormously between tissues and between individuals, rising in obesity and in several disease states. An inhibitor targeting an enzyme whose expression is that variable will produce correspondingly variable effects, and none of the rodent work was designed to characterise that spread.
Human data, where it exists
No controlled human trials of 5-Amino-1MQ have been published. There is no human pharmacokinetic data, no human safety dataset, and no human efficacy evidence for body composition or any other endpoint.
This is worth stating plainly because 5-Amino-1MQ is frequently marketed alongside compounds that do have clinical records, which creates an impression of comparable evidentiary standing. NNMT as a drug target has genuine academic interest and has been the subject of medicinal chemistry programmes, but target validation in rodents is not the same as a compound having been tested in people. The entire human question remains open.
Common assertions, and what the record supports
The claim most commonly made is that 5-Amino-1MQ causes fat loss without dietary change, usually citing the mouse studies where weight reduction occurred without reduced food intake. That description of the rodent result is accurate. The unsupported step is treating a rodent result as a human expectation — mouse adipose metabolism, NNMT expression levels and energy balance differ from human, and the translation rate from rodent obesity models to human efficacy is historically poor.
A second claim positions it as a NAD+ booster equivalent to or better than NMN or NR. The mechanism is genuinely different and arguably more elegant: rather than supplying precursor, it reduces precursor consumption. But no human study has demonstrated that this raises tissue NAD+ in people, which is the step the claim assumes.
A third framing calls it a peptide. It is not; it is a small molecule quinolinium compound.
Against the compounds it is most often confused with
Against the incretin agonists on the same shelf — semaglutide, retatrutide — 5-Amino-1MQ has nothing mechanistically in common. Those are receptor agonists acting on appetite, insulin and gastric emptying, with large human trial datasets. This is an intracellular enzyme inhibitor with none.
Against SLU-PP-332, the pairing is closer in spirit: both are small molecules targeting cellular energy metabolism rather than appetite signalling, and both are rodent-stage. They differ in target — ERR agonism driving mitochondrial biogenesis versus NNMT inhibition sparing NAD+ and SAM.
Against NAD+ itself and its precursors, the relationship is complementary rather than competitive: precursor supplementation adds substrate, NNMT inhibition reduces the drain on it. Neither approach has established in humans that the resulting change in tissue NAD+ produces a functional outcome.
Adverse findings, toxicology gaps, material hazards
The most important risk is the size of the unknown. A compound with no human exposure data has no characterised adverse effect profile, no known interactions and no established safe exposure range. Nothing in this section should be read as implying the profile is benign; it means the studies that would describe it have not been done.
Mechanistically, NNMT is not confined to adipose tissue. It is expressed in liver and appears upregulated in a number of cancers, where its role is under active investigation and not fully resolved. Inhibiting an enzyme with tissue-specific roles in methyl-group handling has consequences for one-carbon metabolism that have not been mapped in a whole organism over time.
Because the compound alters SAM availability, effects on methylation-dependent processes — including epigenetic regulation — are plausible and uncharacterised. Chronic rodent toxicology at the exposures commonly discussed has not been published.
Bench practice for this compound
5-Amino-1MQ is a small molecule rather than a peptide, and it does not share the aggregation and foaming sensitivities of the lyophilized peptides in this catalogue. It is nonetheless supplied as research material and should be handled as such.
Keep the container closed and stored per the conditions given on this page, protected from light and moisture. Solubility characteristics differ from peptide material, so the reconstitution guidance written for lyophilized peptides does not transfer directly. Confirm solvent compatibility against the lot documentation before preparing stock solutions. Because the compound is a permanently charged quaternary salt rather than a neutral peptide, it is markedly hygroscopic; keep the container tightly closed and allow it to reach room temperature before opening, so atmospheric moisture does not condense onto cold material and compromise mass-based measurement.
This summary describes published research. It is not a protocol, not a recommendation, and not a statement that this compound is safe or effective for any use. Not for human or animal use.
Every lot is tested for identity, purity, and net content.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%, on the lot you receive.
Same Shelf
